Delivery Order SPE2DB20D1100-SPE2DB25FE1AS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Jatenzo 237 mg capsules (120 count) valued at $1,640.34. This firm fixed-price delivery order, which is scheduled for completion by August 27, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Jatenzo 237 mg capsules (120 count) with a ceiling value of $2,263.74. This is a firm fixed-price contract with an ultimate completion date of September 18, 2025. The award was competitively made with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,636.67. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $2,263.74. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120 count) under a firm fixed-price contract with a ceiling value of $1,131.87. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $3,347.66 for Jatenzo 198 mg capsules (120-count units) with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 158 mg capsules (120-count unit) under a firm fixed-price contract with a ceiling value of $1,983.45. The award, made on September 8, 2025, is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. This delivery order is executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion...
- The Defense Logistics Agency awarded a delivery order valued at $14,035.64 to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1ASDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,131.87. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this award, indicating competitive selection. The product will be performed and delivered from the vendor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through its extensive portfolio of pharmaceutical and medical supply contracts with DLA. The company maintains a $999,999,999.00 prime indefinite delivery vehicle with DLA Troop Support Medical (designated SPE2DX) extending through December 2026, which supports military healthcare systems globally with a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies. This delivery order for Jatenzo, a testosterone replacement therapy medication, exemplifies the company's role in fulfilling federal medical supply needs across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/24/25 |